Amarillo National Bank Purchases 260 Shares of Pfizer, Inc. (PFE)
Amarillo National Bank increased its position in Pfizer, Inc. (NYSE:PFE) by 1.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,693 shares of the biopharmaceutical company’s stock after buying an additional 260 shares during the quarter. Amarillo National Bank’s holdings in Pfizer were worth $863,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in the stock. Northstar Group Inc. lifted its position in Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 35 shares during the last quarter. Stone House Investment Management LLC lifted its position in Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 66 shares during the last quarter. Naples Global Advisors LLC lifted its position in Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 79 shares during the last quarter. Alpha Windward LLC lifted its position in Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock valued at $287,000 after purchasing an additional 89 shares during the last quarter. Finally, Asset Planning Services Ltd. lifted its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 137 shares during the last quarter. Institutional investors own 69.00% of the company’s stock.
PFE has been the subject of several recent research reports. UBS AG reiterated a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research report on Monday, July 31st. Cowen and Company set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Monday, July 10th. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets reiterated a “buy” rating and issued a $37.00 price objective on shares of Pfizer in a research report on Wednesday, September 6th. Finally, Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Tuesday. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $38.21.
Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.3215% during midday trading on Thursday, reaching $35.8444. The company had a trading volume of 5,601,574 shares. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $36.24. The stock has a market capitalization of $213.18 billion, a price-to-earnings ratio of 26.2212 and a beta of 1.00. The firm’s 50 day moving average price is $34.55 and its 200-day moving average price is $33.66. Pfizer also was the target of some unusual options trading on Monday. Stock investors acquired 24,211 call options on the company. This is an increase of 129% compared to the typical volume of 10,577 call options.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. Pfizer’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.64 EPS. Equities research analysts expect that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.56%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/amarillo-national-bank-purchases-260-shares-of-pfizer-inc-pfe/1610790.html.
In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the sale, the insider now directly owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is currently owned by corporate insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.